Tianjin Lisheng Pharmaceutical Co Ltd Financial Flexibility Index
Tianjin Lisheng Pharmaceutical Co Ltd financial flexibility index. Tianjin Lisheng Pharmaceutical Co Ltd (002393) has a Financial Flexibility Index of 0.35x as of December 2025. Free cash flow of CN¥307.91 Million (operating CF CN¥287.81 Million minus capex CN¥20.11 Million) represents 0% of total liabilities (CN¥890.89 Million). See 002393 free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Financial Flexibility Index of Tianjin Lisheng Pharmaceutical Co Ltd (2007–2025)
Financial flexibility index of Tianjin Lisheng Pharmaceutical Co Ltd from 2007 to 2025. Historical Financial Flexibility Index trend for Tianjin Lisheng Pharmaceutical Co Ltd across 19 annual periods. Check Tianjin Lisheng Pharmaceutical Co Ltd (002393) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Tianjin Lisheng Pharmaceutical Co Ltd Financial Flexibility Index by Year (2007–2025)
Tianjin Lisheng Pharmaceutical Co Ltd financial flexibility index by year from 2007 to 2025. Year-by-year free cash flow to debt coverage for Tianjin Lisheng Pharmaceutical Co Ltd. For the full cash flow conversion analysis, see 002393 cash flow conversion.
| Year | Flexibility Index | Free Cash Flow (CNY) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.55x | CN¥489.31 Million | CN¥451.85 Million | CN¥890.89 Million | ▲ +281.2% |
| 2024 | 0.14x | CN¥142.01 Million | CN¥88.26 Million | CN¥985.54 Million | ▼ -53.4% |
| 2023 | 0.31x | CN¥271.23 Million | CN¥209.51 Million | CN¥877.17 Million | ▼ -21.8% |
| 2022 | 0.40x | CN¥372.30 Million | CN¥331.38 Million | CN¥941.66 Million | ▲ +8.4% |
| 2021 | 0.36x | CN¥284.58 Million | CN¥196.34 Million | CN¥780.42 Million | ▲ +48.3% |
| 2020 | 0.25x | CN¥177.03 Million | CN¥76.37 Million | CN¥720.09 Million | ▼ -41.4% |
| 2019 | 0.42x | CN¥358.78 Million | CN¥268.33 Million | CN¥855.85 Million | ▲ +10.6% |
| 2018 | 0.38x | CN¥267.12 Million | CN¥162.69 Million | CN¥704.85 Million | ▼ -0.5% |
| 2017 | 0.38x | CN¥229.34 Million | CN¥179.25 Million | CN¥602.32 Million | ▼ -42.3% |
| 2016 | 0.66x | CN¥310.80 Million | CN¥173.60 Million | CN¥470.60 Million | ▼ -27.9% |
| 2015 | 0.92x | CN¥402.73 Million | CN¥198.13 Million | CN¥439.50 Million | ▼ -14.7% |
| 2014 | 1.07x | CN¥362.89 Million | CN¥72.24 Million | CN¥337.89 Million | ▼ -46.9% |
| 2013 | 2.02x | CN¥602.72 Million | CN¥289.62 Million | CN¥298.20 Million | ▼ -37.0% |
| 2012 | 3.21x | CN¥475.07 Million | CN¥250.72 Million | CN¥148.13 Million | ▼ -31.6% |
| 2011 | 4.69x | CN¥300.53 Million | CN¥134.58 Million | CN¥64.07 Million | ▲ +41.2% |
| 2010 | 3.32x | CN¥256.24 Million | CN¥186.55 Million | CN¥77.12 Million | ▲ +539.3% |
| 2009 | 0.52x | CN¥213.74 Million | CN¥196.14 Million | CN¥411.26 Million | ▼ -26.5% |
| 2008 | 0.71x | CN¥191.45 Million | CN¥126.59 Million | CN¥270.58 Million | ▲ +65.5% |
| 2007 | 0.43x | CN¥188.86 Million | CN¥174.94 Million | CN¥441.87 Million | — |